Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia

Leuk Lymphoma. 2005 Jun;46(6):925-7. doi: 10.1080/10428190500052248.

Abstract

The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present observation indicates that caution should be exercised in using high cumulative doses of DNA topoisomerase II inhibitors in such patients.

Publication types

  • Case Reports

MeSH terms

  • Burkitt Lymphoma / complications
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / genetics
  • Burkitt Lymphoma / immunology*
  • Child
  • Chromosomes, Human, Pair 4*
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation*
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Immunophenotyping / methods
  • Male
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Myeloid-Lymphoid Leukemia Protein / metabolism
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Time Factors
  • Topoisomerase II Inhibitors
  • Translocation, Genetic*
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • KMT2A protein, human
  • Topoisomerase II Inhibitors
  • Myeloid-Lymphoid Leukemia Protein
  • Histone-Lysine N-Methyltransferase